World Mosquito Program Noumea - Human Sample Component
1 other identifier
observational
500
1 country
1
Brief Summary
The dengue, Zika and chikungunya arboviruses represent potentially severe infections to which the New Caledonian population is exposed. In the absence of specific treatment or vaccine, vector control remains the method of choice to limit their spread. However, the traditional methods of prevention and vector control measure today face their limits: mosquito resistance to insecticides, difficulty of access and destruction of breeding areas... The World Mosquito Program Noumea project is based on the artificial colonization of the mosquito vector Aedes aegypti by the endosymbiotic bacteria Wolbachia, which reduces its ability to transmit arboviruses. The breeding of mosquitoes carrying the bacterium Wolbachia in the laboratories of the Institut Pasteur of New Caledonia requires the use of human blood samples for mosquito gorging. The objective of the research is to generate, maintain and amplify Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria for the planned insect release program in Noumea.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 28, 2018
CompletedFirst Posted
Study publicly available on registry
June 11, 2018
CompletedStudy Start
First participant enrolled
June 25, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2023
CompletedFebruary 15, 2022
February 1, 2022
4.9 years
May 28, 2018
February 14, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Generation of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria
Generation of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria for the planned insect release program in Noumea by measuring the Aedes aegypti female gorging rate
36 months
Maintenance and amplification of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria
Maintenance and amplification of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria for the planned insect release program in Noumea by measuring the number of eggs per Aedes Aegypti female gorged
36 months
Secondary Outcomes (1)
Vector competence assessment of the different Aedes aegypti Caledonian lineages
36 months
Study Arms (2)
Hemochromatosis or polycythemia patients
Blood samples from hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications. Blood bag (volume of blood: from 450 to 500 mL).
Healthy donors
Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).
Interventions
Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
Blood samples are from blood donations of healthy donors.
Eligibility Criteria
Hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications, and healthy donors.
You may qualify if:
- All adult hemochromatosis or polycythemia patients or healthy donors have given their written consent to participate in the study and for the collection of a blood sample.
You may not qualify if:
- Participation refusal
- Minor person
- Positive result by Reverse transcription polymerase chain reaction RT-PCR for arboviruses
- Invalid qualification of the blood donation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Institut Pasteurlead
- Institut Pasteur of New Caledoniacollaborator
Study Sites (1)
Centre Hospitalier de Nouvelle-Calédonie
Nouméa, Nouvelle-Calédonie, 98 849, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Frédéric Touzain
Hospital Center of New Caledonia
- PRINCIPAL INVESTIGATOR
Myrielle Dupont-Rouzeyrol
Institut Pasteur of New Caledonia
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 28, 2018
First Posted
June 11, 2018
Study Start
June 25, 2018
Primary Completion
June 1, 2023
Study Completion
June 1, 2023
Last Updated
February 15, 2022
Record last verified: 2022-02